First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Benjamin Solomon, Holger Thurm et al.|New England Journal of Medicine|2020Cited by 1.1k
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialNancy Y. Lee, Ezra E.W. Cohen, Robert L. Ferris et al.|The Lancet Oncology|2021Cited by 618
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN StudyBenjamin Solomon, Tony Mok, Todd M. Bauer et al.|Journal of Clinical Oncology|2022Cited by 133
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Julie R. Park et al.|Nature Medicine|2023Cited by 125
910O Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)Ezra E.W. Cohen, N. Lee, Robert L. Ferris et al.|Annals of Oncology|2020Cited by 42